Kennedy Institute of Rheumatology, Amgen Incorporated

Date:
2002
Reference:
SA/KET/A/7/3
Part of:
The Kennedy Trust for Rheumatology Research
  • Archives and manuscripts

About this work

Description

Papers relating to Australian Kennedy Institute of Rheumatology patent application "Anti-TNF Antibodies and Methotrexate in the Treatment of Autoimmune Disease" and opposition from Amgen Inc. Includes evidence in support and expert declarations. Item also contains papers relating to Japanese Kennedy Institute of Rheumatology patent application "Truncated TNF Receptor (also known as "Modified Human TNF alpha Receptor" and "Soluble Human TNF Receptor ") and opposition to this patent from Amgen Inc including a declaration of Kennedy Institute staff.

Publication/Creation

2002

Physical description

1 file (in 3 parts)

Terms of use

This item is closed and cannot be accessed. Please see our Access Policy for more details. Closed until 1 January 2033.

Where to find it

  • LocationStatusAccess
    Closed stores
    ClosedCan't be requested

Permanent link